Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.

Hunter SM, Rowley SM, Clouston D; KCon Fab Investigators, Li J, Lupat R, Krishnananthan N, Risbridger G, Taylor R, Bolton D, Campbell IG, Thorne H.

Urol Oncol. 2016 Mar;34(3):120.e9-16. doi: 10.1016/j.urolonc.2015.10.009. Epub 2015 Nov 14.

PMID:
26585945
2.

Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.

Catts ZA, Baig MK, Milewski B, Keywan C, Guarino M, Petrelli N.

Ann Surg Oncol. 2016 May;23(5):1729-35. doi: 10.1245/s10434-015-5026-x. Epub 2016 Jan 4.

PMID:
26727920
3.

Mutational landscape of candidate genes in familial prostate cancer.

Johnson AM, Zuhlke KA, Plotts C, McDonnell SK, Middha S, Riska SM, Schaid DJ, Thibodeau SN, Douglas JA, Cooney KA.

Prostate. 2014 Oct;74(14):1371-8. doi: 10.1002/pros.22849. Epub 2014 Aug 11.

4.

BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.

Waddell N, Ten Haaf A, Marsh A, Johnson J, Walker LC; kConfab Investigators, Gongora M, Brown M, Grover P, Girolami M, Grimmond S, Chenevix-Trench G, Spurdle AB.

PLoS Genet. 2008 May 23;4(5):e1000080. doi: 10.1371/journal.pgen.1000080.

5.

BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.

Cherbal F, Salhi N, Bakour R, Adane S, Boualga K, Maillet P.

Dis Markers. 2012;32(6):343-53. doi: 10.3233/DMA-2012-0893.

6.

Germline Variants of Prostate Cancer in Japanese Families.

Hayano T, Matsui H, Nakaoka H, Ohtake N, Hosomichi K, Suzuki K, Inoue I.

PLoS One. 2016 Oct 4;11(10):e0164233. doi: 10.1371/journal.pone.0164233. eCollection 2016.

7.

Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM.

Eur Urol. 2015 Mar;67(3):496-503. doi: 10.1016/j.eururo.2014.08.007. Epub 2014 Aug 22.

PMID:
25154392
8.

BRCA1 and BRCA2 have a limited role in familial prostate cancer.

Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ.

Cancer Res. 2000 Mar 1;60(5):1371-5.

9.

Candidate colorectal cancer predisposing gene variants in Chinese early-onset and familial cases.

Zhang JX, Fu L, de Voer RM, Hahn MM, Jin P, Lv CX, Verwiel ET, Ligtenberg MJ, Hoogerbrugge N, Kuiper RP, Sheng JQ, Geurts van Kessel A.

World J Gastroenterol. 2015 Apr 14;21(14):4136-49. doi: 10.3748/wjg.v21.i14.4136.

10.

Whole-exome sequencing of Finnish hereditary breast cancer families.

Määttä K, Rantapero T, Lindström A, Nykter M, Kankuri-Tammilehto M, Laasanen SL, Schleutker J.

Eur J Hum Genet. 2016 Jan;25(1):85-93. doi: 10.1038/ejhg.2016.141. Epub 2016 Oct 26.

11.

Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy.

Norton N, Li D, Rampersaud E, Morales A, Martin ER, Zuchner S, Guo S, Gonzalez M, Hedges DJ, Robertson PD, Krumm N, Nickerson DA, Hershberger RE; National Heart, Lung, and Blood Institute GO Exome Sequencing Project and the Exome Sequencing Project Family Studies Project Team.

Circ Cardiovasc Genet. 2013 Apr;6(2):144-53. doi: 10.1161/CIRCGENETICS.111.000062. Epub 2013 Feb 15.

12.

Screening for familial and hereditary prostate cancer.

Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I.

Int J Cancer. 2016 Jun 1;138(11):2579-91. doi: 10.1002/ijc.29949. Epub 2016 Feb 5. Review.

13.

Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.

Li N, Rowley SM, Thompson ER, McInerny S, Devereux L, Amarasinghe KC, Zethoven M, Lupat R, Goode D, Li J, Trainer AH, Gorringe KL, James PA, Campbell IG.

Breast Cancer Res. 2018 Jan 9;20(1):3. doi: 10.1186/s13058-017-0929-z.

14.

Whole-genome Linkage Analysis and Sequence Analysis of Candidate Loci in Familial Breast Cancer.

Marikkannu R, Aravidis C, Rantala J, Picelli S, Adamovic T, Keihas M, Liu T, Kontham V, Nilsson D, Lindblom A.

Anticancer Res. 2015 Jun;35(6):3155-65.

PMID:
26026075
15.

BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population.

Dębniak T, Scott RJ, Górski B, Masojć B, Kram A, Maleszka R, Cybulski C, Paszkowska-Szczur K, Kashyap A, Murawa D, Malińska K, Kiedrowicz M, Rogoża-Janiszewska E, Rudnicka H, Deptuła J, Domagała P, Kluźniak W, Lener MR, Lubiński J.

PLoS One. 2018 Oct 4;13(10):e0204768. doi: 10.1371/journal.pone.0204768. eCollection 2018.

16.

Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.

Rutter JL, Smith AM, Dávila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP.

Hum Mutat. 2003 Aug;22(2):121-8.

PMID:
12872252
17.

Clinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.

Surowy HM, Sutter C, Mittnacht M, Klaes R, Schaefer D, Evers C, Burgemeister AL, Goehringer C, Dikow N, Heil J, Golatta M, Schott S, Schneeweiss A, Bugert P, Sohn C, Bartram CR, Burwinkel B.

Breast Cancer Res Treat. 2014 Jun;145(2):451-60. doi: 10.1007/s10549-014-2943-5. Epub 2014 Apr 12.

PMID:
24728577
18.

Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.

Kapoor NS, Curcio LD, Blakemore CA, Bremner AK, McFarland RE, West JG, Banks KC.

Ann Surg Oncol. 2015 Oct;22(10):3282-8. doi: 10.1245/s10434-015-4754-2. Epub 2015 Jul 29.

PMID:
26219241
19.

Germline BRCA mutation in male carriers-ripe for precision oncology?

Leão RRN, Price AJ, James Hamilton R.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):48-56. doi: 10.1038/s41391-017-0018-5. Epub 2017 Dec 14. Review.

PMID:
29242595
20.

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.

Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH.

Breast Cancer Res. 2012 Apr 16;14(2):R66.

Supplemental Content

Support Center